⏱ 15 min read
Hospital 366 Days · Case No. 15
The hospital’s year does not end at 365. It runs to 366, and keeps going.
Call her Fern. Age, occupation, location, and any potentially identifying details have been changed. The clinical pattern is a composite reconstructed from cases that American emergency rooms see repeatedly over a year, and it does not represent any specific patient.
A Watchman device is meant to lower the risk of stroke, but the blood thinner that guards a patient until it seals has one job, which is to keep blood from clotting. That is also the reason it can turn a small leak in the stomach into a slow emergency. The same drug that prevents a stroke can, in the wrong week, drain a person of a third of their blood without a single drop of visible bleeding.
Atrial fibrillation raises the risk of stroke about fivefold, because blood pools in a pocket of the heart and can throw a clot to the brain. (AHA/ACC 2023) The standard defense is lifelong anticoagulation. For people who cannot carry that drug safely, there is a device that closes the pocket instead. The Watchman device is built for exactly that problem.
But the device does not work the day it goes in. For about 45 days the anticoagulant stays on while tissue grows over the device and seals it. That window, meant as a bridge to safety, is also the stretch when a patient is most exposed to bleeding. (Circ Cardiovasc Interv 2023)
Here, a 72-year-old woman one week past a Watchman device walked into an emergency room with three days of black stool and a hemoglobin at a third of normal. The thing built to lower her stroke risk had not yet sealed, and the drug holding the line until then had started a bleed.
This is not the story of every patient with a Watchman device. It is a look, in numbers, at why the 45-day window carries a bleeding risk that is easy to miss, and at the bind a clinician faces when stopping the bleed and preventing the stroke pull in opposite directions.
A Watchman Device, One Week On
Fern was 72 and retired. She lived alone after losing her husband, and her daughter lived nearby. A week before this admission she had two procedures done at once: an ablation to control her heart rhythm, and the placement of a Watchman device to lower her stroke risk.
She had a few conditions that mattered for reading this bleed. High blood pressure, high cholesterol, gastroesophageal reflux disease (GERD), and paroxysmal atrial fibrillation. She had managed anxiety and depression for years, and she was prediabetic. She used a CPAP machine every night for sleep apnea. A colonoscopy two years earlier had found and removed a few polyps.
She was still taking apixaban (Eliquis) twice a day. Keeping the anticoagulant going one week after the device was not an oversight. It is what the protocol calls for, because the device has not yet sealed. She drank moderately, about twice a week, and she did not smoke.
On the third morning of black, sticky stool, she felt dizzy standing up from a chair and her heart was racing. Her daughter took one look and drove her to the emergency room, about twenty-five minutes away.
Three Days of Black Stool to the ER
Day 1 after the procedure. Fern went home from the device placement. The apixaban was still in her pill organizer, to continue until the device sealed.
Day 5 (first day of black stool). The morning stool was dark and sticky. She wondered whether something she ate had iron in it and let it go.
Day 6 (second day). The color was darker. She felt slightly nauseated but did not vomit, and felt dizzy once standing up.
Day 7 (third day). She had to hold the edge of the sink to stand. Her heart was beating fast. She called her daughter, who drove her in.
At the emergency room. Vital signs, blood work, and an assessment for a gastrointestinal bleed were done. The hemoglobin came back critically low.
Decision to admit. Fluids and a transfusion of packed red cells were started, the apixaban was stopped, and she was admitted for an urgent upper endoscopy and serial hemoglobin checks.
Watchman Device Bleeding Workup: What the Tests Found
Triage vitals: blood pressure 96/58 and dropping further on sitting up (orthostatic), heart rate 108 (fast and weak), respiratory rate 18, oxygen saturation 97%, no fever. Skin pale, fingertips cold.
ECG and rhythm: a fast rate consistent with blood loss, no acute ischemic changes.
Blood work: hemoglobin 5.4 g/dL, less than half the lower limit of normal for an adult woman, a level that calls for immediate transfusion. Blood urea nitrogen (BUN) 38 mg/dL, elevated, which is common in upper gastrointestinal bleeding as digested blood protein is absorbed and blood volume falls. Glucose 158 mg/dL, mildly high.
Stool finding: melena, the black and sticky stool of upper gastrointestinal bleeding. Blood leaks in the stomach or duodenum, then darkens as it is digested moving through the gut. For melena to appear, bleeding usually has to run for several days in a meaningful amount.
The admitting team’s orders read this way. Admit to medicine. Gastroenterology consult and preparation for urgent upper endoscopy (EGD). Vital signs every hour, serial hemoglobin checks. Hold the apixaban and plan reversal of the anticoagulant if the bleeding does not settle. Upper bleeding was the most likely source, but the polyps found two years earlier meant a lower source had to be checked as well, with the upper tract examined first.
Taken together, the picture was an active upper gastrointestinal bleed on an anticoagulant, found during the 45-day window after a Watchman device when the drug cannot simply be left off. That last point is what made the decision hard: the same drug fueling the bleed was the one still guarding against a stroke.
Plain-Language Reference
| Term | What It Means in Plain Language |
|---|---|
| Watchman device | A small umbrella-shaped device that closes off the left atrial appendage of the heart to prevent stroke. |
| Left atrial appendage (LAA) | A dead-end pouch in the heart where clots form most easily in atrial fibrillation. |
| Apixaban (Eliquis) | An anticoagulant that thins the blood by blocking clotting factor Xa. |
| Melena | Black, sticky, tar-like stool. A sign of upper gastrointestinal bleeding. |
| EGD (upper endoscopy) | A camera passed through the mouth to view the esophagus, stomach, and duodenum. |
| Anticoagulant reversal | Steps taken to undo a blood thinner’s effect so bleeding can stop, using clotting-factor products such as 4-factor PCC. |
| 4F-PCC (Kcentra) | Four-factor prothrombin complex concentrate, a clotting-factor product used to help reverse major bleeding. |
| TEE (transesophageal echo) | An ultrasound probe passed down the esophagus to view the heart and the device seal. |
| Clinical Marker | Patient’s Presentation | Significance & Reference Literature |
|---|---|---|
| Hemoglobin | 5.4 g/dL | Less than half the lower limit of normal for an adult woman. A level at which immediate transfusion is the standard step in major bleeding (AHA/ACC 2023). |
| Stool Finding | Melena, 3 days | Black, tar-like stool points to an upper gastrointestinal source. In apixaban-related GI bleeds, melena is the most common presentation and the stomach a common site (Cureus 2024). |
| Blood Urea Nitrogen | 38 mg/dL (elevated) | A rise that fits upper GI bleeding, as digested blood protein is absorbed and blood volume falls. It supports a slow leak over days rather than a single sudden bleed. |
| Days Since Device | 7 of ~45 | Inside the post-procedure window when the anticoagulant must stay on until a 45-day TEE confirms the seal. The stretch of highest bleeding exposure (Circ Cardiovasc Interv 2023). |
| Reversal Trade-off | Clot risk rises | Undoing the anticoagulant to stop the bleed returns the patient to a clot-prone state. The trade-off between bleeding and clotting is the central tension of the case (NEJM 2019). |
Three days of black stool, a hemoglobin at a third of normal, and a bleed that began inside the 45-day window after a Watchman device.
From the Reviewer · Eleanor Hayes, M.D.
(A) What the Watchman device actually does
In atrial fibrillation, the clot that causes a stroke forms in one place most of the time, the left atrial appendage. The Watchman device closes off the mouth of that pouch. It was designed for patients who cannot tolerate a lifelong anticoagulant, especially those at high risk of bleeding, as a way to replace the drug. The indication is nonvalvular atrial fibrillation in a patient who needs long-term anticoagulation but has a reason it is hard to continue.
(B) Why the patient was still on apixaban a week later
Placing the device does not mean the anticoagulant stops that day. At first the surface of the device still allows blood to pass, and it takes time for tissue to grow over it and seal it. The standard protocol keeps the patient on the anticoagulant plus aspirin for about 45 days, then uses a transesophageal echo at day 45 to confirm there is no leak and no clot before the anticoagulant is stopped. (JTCVS review 2022) Taking apixaban one week after the procedure was not a break from the protocol. It was exactly what the protocol calls for.
(C) The period before the device seals
It helps to see where this patient stood. She received the device in order to avoid a lifelong anticoagulant because of bleeding risk, and the bleeding happened during the roughly 45 days it takes for the device to seal. In the PROTECT-AF and PREVAIL trials, the schedule that became standard combined warfarin and aspirin for 45 days after the procedure, then switched to dual antiplatelet therapy through six months. (Circ Cardiovasc Interv 2023) That window is also the stretch when a patient is most exposed to bleeding.
(D) Why GERD and an anticoagulant make a dangerous pair
Acid reflux irritates the lining of the upper gastrointestinal tract over time. Add a drug that blocks clotting, and bleeding that starts in a small erosion or ulcer can fail to stop and build up over several days. In reported series of apixaban-related gastrointestinal bleeding, most patients present with melena, the stomach is a common site, and peptic ulcer is a common cause. (Cureus 2024) That fits this patient.
(E) Reading the numbers
A hemoglobin of 5.4 is an emergency by itself. What stands out is that this patient walked in. A single massive bleed would have brought shock before this point. A slow leak over several days that dragged the hemoglobin down to 5.4 is the better fit, and the elevated BUN supports that reading.
(F) The reversal decision
Here comes the hardest decision. To stop the bleeding, the effect of apixaban has to be undone. That is what reversal means: giving something that lets the blood clot again. But the moment the blood can clot again, the patient is back in the state the anticoagulant was preventing, which in atrial fibrillation is a stroke. The reversal is necessary and it carries its own danger, and that tension is the center of this case.
(G) The reversal drug that came and went
For a few years there was a drug aimed directly at this problem. Andexanet alfa (Andexxa) was approved in the United States in 2018 as the first agent built specifically to reverse factor Xa inhibitors like apixaban. (StatPearls) Its later trial data, though, showed that reversal carried a real clotting cost. Just over 10% of patients given the drug had at least one thrombotic event, against 5.6% with usual care. (Medscape 2025) The FDA concluded the risks outweighed the benefits, and the manufacturer withdrew the drug from the U.S. market on December 22, 2025. (TCTMD 2025) The reason it left is the same lesson this case turns on: undoing a blood thinner can trade a bleed for a clot.
(H) What reversal looks like now
With that drug off the U.S. market, the reversal of a factor Xa inhibitor bleed leans on a clotting-factor product already familiar in hospitals, four-factor prothrombin complex concentrate (4F-PCC, Kcentra). In major bleeding on a factor Xa inhibitor, 4F-PCC at 25 to 50 units per kilogram has shown moderate effectiveness, near 69%, with a low thrombotic event rate around 2.3%. (DOAC guidance 2025) It is not a perfect antidote, but it is what most teams reach for, alongside stopping the drug and transfusing.
(I) The price of reversal, whichever route
Whatever the method, undoing the anticoagulant returns the patient to a state where clots form easily. The event a patient with atrial fibrillation fears most is an arterial clot, which is a stroke. To stop the bleed the clotting risk goes up, and to prevent the clot the bleeding risk goes up. The single-arm trial of the older reversal drug captured the size of that danger: thrombotic events in 9.7% of 352 patients within 30 days, and 30-day mortality of 13.9%. (NEJM 2019)
(J) The gap itself
Even without any reversal product, stopping the anticoagulant to control the bleed raises the clot risk on its own. Among patients who had a major bleed while on a direct oral anticoagulant, thrombotic events rose from about 4% at one week to about 10% at four weeks off the drug. (ClinicalTrials.gov) The longer the anticoagulant stays off the higher the stroke risk, and restarting it raises the rebleeding risk.
(K) What happened next in cases like this
Even when the bleeding is stopped, there is a pattern in which an embolic event arrives during the few days the anticoagulant is held. When a patient like this develops weakness in one arm or slurred speech, it can be the sign that a clot from the left atrial appendage has blocked a vessel in the brain. In cases like this, stopping the anticoagulant to control the bleed raises the risk of the very clot the device was meant to prevent. After such an event, the time to restart the anticoagulant depends on the size of the infarct, with one reference point being within 48 hours for a small or moderate stroke and at day 6 or 7 for a large one. (Practical Neurology 2023)
(L) What Bends the Curve
A few things sit outside the emergency room and shape how a case like this turns out. None of them is answered in the ER itself.
- Know the 45-day window. The period when the anticoagulant stays on after the device is the stretch of highest bleeding risk, and black stool, dizziness, or a fast pulse during it are signs that point to bleeding.
- Treat the GERD actively. A chronically irritated upper tract is the soil in which an anticoagulant-driven bleed takes hold.
- Account for living alone. Patients without someone nearby to check a worrying sign against tend to arrive at the emergency room later, after more blood has been lost.
- Plan the restart in advance. When and how the anticoagulant goes back on after the bleed is its own decision, balancing rebleeding against stroke.
These belong to the patient and the cardiology and gastroenterology teams. The summary above is only the picture before those decisions are made.
Two Costs, One Decision Window
| Clinical & Behavioral Scenarios | Estimated Facility Billing | Patient Out-of-Pocket (PPO) |
|---|---|---|
| (1) Bleeding caught early: ER, transfusion, endoscopic hemostasis, short admission | ~$11,000 to $20,000 | Deductible + coinsurance |
| (2) Arrival after days of bleeding: larger transfusion, ICU, reversal with 4F-PCC, rebleed readmission | ~$60,000 to $85,000+ | Annual OOP max likely |
| (3) An embolic event (stroke) occurs during the anticoagulation gap | $19,000 hospitalization, ~$140,000 lifetime | Annual OOP max + possible lasting disability |
| (4) Years of follow-up: anticoagulation plan, GERD control, blood pressure | $1,000 to $4,000 (per year) |
Manageable range |
Sources: PMC 2023 (UGIB hospitalization cost); PMC 2025 (rebleed readmission); PMC (stroke hospitalization cost). Facility and out-of-pocket figures are scenario estimates for a typical PPO and vary by plan and region.
The most expensive scenario is not the visit that was made early. It is the bleed that ran for days and the stroke that can follow when the anticoagulant comes off. An upper gastrointestinal bleed hospitalization averages about $11,228, with 12-month spending near $20,405 (PMC 2023), while a rebleed readmission runs near $82,545 against about $61,521 without one (PMC 2025). An ischemic stroke adds roughly $18,963 for the hospitalization and a mean lifetime cost near $140,048 (CEOR 2016). In Fern’s case the bleed was the event in front of the team, but the anticoagulation gap it forced open was the harder variable to manage.
The same connection between a heart rhythm drug and a missed signal runs through the case of a man after an ablation whose anticoagulation and an unfilled diuretic set the path of an admission. How stopping a cardiac medication can move a patient toward decompensation is laid out in the case where stopping blood pressure medication led to heart failure. And the same pattern of a serious finding turning up while looking for something else appears in the case of a month of back pain that turned out to be multiple myeloma.
Tools for Reading Heart and Health Numbers
A single result rarely tells the whole story. Three calculators that help frame blood-panel, heart, and longevity numbers against age-matched references.
· Blood Work Decoder (Cardiac & Metabolic Panel Reader)
· Heart Age Calculator (Cardiovascular Risk Estimate)
· Life Calculator (Longevity Estimate)
Fern was stabilized once the bleeding was controlled and the transfusion brought her hemoglobin back up. The emergency room and the admission finished one thing. They accounted for why three days of black stool on an anticoagulant needed urgent care, and they stopped the active bleed.
What did not close was the rest. When and how the anticoagulant goes back on, how to protect the upper tract from another bleed, and how to carry her safely through the days the drug is held are the agenda for the inpatient team and the follow-up that comes after. The device was meant to lower one risk. The window before it sealed opened another, and the work of the next stretch is to bring the two back into balance.
This article is for general information and does not provide medical advice. The case described is a composite reconstructed from publicly reported clinical patterns and does not represent any specific patient. Black stool, dizziness, or other signs of bleeding should be evaluated urgently rather than judged at home. Prescribed medications, especially anticoagulants, should never be stopped or adjusted on your own.
Take care of yourself. Nobody else will do it for you.
Wilbur P is the editor of Manclub, leading coverage across health and life. His work is research-driven and built on primary sources a reader can verify – written for men in the second half of life who would rather know than believe. Based in Florida, still learning and still in the fight. Corrections, questions, story tips: [email protected].